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Table 2. Primary and secondary outcomes
Baseline Week 12 Change 95% CI
Responder (%)1 47 40 to 54
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS PGA (0-10) (SD) 6.9 (2) 5.6 (2) 1.3 (2) -0.9 to -2
WOMAC-scores, mean (SD)2
pain 57 (19) 52 (23) -5.1 (19) -2 to -8
stiffness 62 (20) 58 (23) -3.8 (23) 0 to -8
function 58 (19) 52 (23) -5.6 (19) -3 to -8
1According to OMERACT-OARSI criteria; 2Scores are normalized (0-100; 0 = no symp-
toms). NRS, numeric rating scale;WOMAC-score,Western Ontario McMaster Universities
score; BMI, body mass index.
Results after 12 weeks are depicted in Table 2. OMERACT-OARSI responder
criteria were fulﬁlled in 47%; 39% reached NRS pain ≤4. In the univariate
analysis, NRS pain at baseline and low number of NSAIDs used for OA were
signiﬁcantly associated with an OMERACT-OARSI response, with only the
latter remaining as independent predictor for OMERACT-OARSI response
after 12 weeks in the multivariate analyses (OR 0.8, p = 0.03). No other
predictors were identiﬁed.
Conclusions: Basic ﬁrst-line recommended conservative treatment options
have not been adequately utilized prior to referral to secondary care in the
large majority of patients, but implementation is feasible and successful
in 47%. Furthermore, response was associated with (lack of) previous
conservative treatment.
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Purpose: Acetaminophen has been for decades recommended as a ﬁrst
line analgesic for osteoarthritis (OA) by consensus guidelines. However,
a recent update of the evidence led OARSI investigators to infer that
evidence for its eﬃcacy has diminished in strength. Furthermore, concerns
have also emerged in respect of its safety. We aimed to reassess the role
of acetaminophen, including the extended release formulation, in OA by
systematic review and latest evidence synthesis of studies reporting data
on its eﬃcacy and safety.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS, Google Scholar,
ISI Web of Science and Cochrane database from inception to April 2010.
We also hand searched review articles, manuscripts and supplements
from medical journals and contacted authors for unpublished data. We
included all human randomized clinical trials comparing acetaminophen
with placebo for OA. Two reviewers (RB, UD) independently performed
data extraction and assessed the quality of each trial. We computed effect
sizes for pain, function and stiffness (change from baseline) for each study
using Hedges’ g statistic corrected for small sample sizes. Effect sizes were
pooled using DerSimonian and Laird random effects model. Heterogeneity
was estimated with the help of I2 statistic. Sub group analyses were
undertaken for pain to determine whether the quality of trials inﬂuences
the results. Relative risk was calculated for any adverse event, GI events
and withdrawals due to adverse events.
Results: The 10 eligible trials included 3004 participants (acetaminophen
- 1515; placebo - 1489) with an age range of 56 to 70 years. They were
published between 1983 and 2007. Eight trials used immediate release
acetaminophen and two trials used extended release acetaminophen as an
active agent. The sample sizes varied between 25 and 779 with a mean of
300; 3 trials had a sample size less than 100. Trial duration ranged from 1 to
24 weeks. Allocation concealment was adequate in 4 trials. Intent-to-treat
analysis results were reported in 8 trials. Dropout rates ranged from 7 to
30% with 4 trials reporting >20%. Seven were industry sponsored trials and
one was sponsored by NIH.
For pain, we found a pooled effect size (ES) of 0.18 (95%CI 0.11, 0.25) favor-
ing acetaminophen with a heterogeneity score (I2) of 0% (Table 1A, Figure
1). For function, ES was 0.16 (95%CI 0.01, 0.31) favoring acetaminophen.
For stiffness, ES was 0.20 (95%CI 0.09, 0.32) favoring acetaminophen. The
sub group analyses showed no difference in eﬃcacy between different
formulations (Table 1B). However, safety analysis showed increase risk
in GI adverse events, more signiﬁcantly among the trials reporting liver
function tests (RR = 4.13 (2.11, 8.07) (Table 1C).
Table 1. Meta-analysis results
A. Pooled effect sizes (95% CI)
Trials N ES (95% CI) I2 (%)
Pain 9 2979 0.18 (0.11, 0.25) 0
Function 5 1915 0.16 (0.01, 0.31) 59
Stiffness 4 1218 0.20 (0.09, 0.32) 5
B. Sensitivity analyses for pain
Trials N ES (95% CI) I2 (%)
Immediate Release Acetaminophen 7 2112 0.17 (0.08, 0.25) 0
Extended Release Acetaminophen 2 867 0.21 (0.08, 0.35) 0
Intent-to-treat Analysis 8 2919 0.17 (0.10, 0.25) 0
Allocation Concealment 4 1247 0.25 (0.14, 0.36) 0
N > 100 7 2862 0.17 (0.10, 0.25) 0
C: Adverse events (Relative Risk)
Trials N RR (95% CI) I2 (%)
Any adverse events 9 2981 1.02 (0.93, 1.11) 0
Withdrawals due to adverse events 8 2683 1.21 (0.89, 1.65) 0
Any gastrointestinal adverse events 8 3373 1.40 (1.03, 1.89) 47
Increased hepatic enzyme levels 3 1079 4.13 (2.11, 8.07) 0
Figure 1. Forest plot.
Conclusions: This meta-analysis conﬁrms eﬃcacy of acetaminophen over
placebo, albeit at a low level barely reaching the minimal clinical thresh-
old. We also detected increase risk in GI adverse events with signiﬁcant
increases in liver enzymes. Therefore, acetaminophen as a short-term
analgesic in OA may still have utility, but with a questionable safety proﬁle.
Future randomized trials should include a longer duration of follow-up to
fully evaluate safety.
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Purpose: To assess the long-term ability of ASU to slow radiographic
progression in symptomatic hip OA
